Predict your next investment

HEALTHCARE | Biotechnology
arciontherapeutics.com

See what CB Insights has to offer

Stage

Debt - IV | Alive

Total Raised

$17M

Last Raised

$1.5M | 9 yrs ago

About Arcion Therapeutics

Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's core technology is based on research which showed that in many neuropathic pain conditions, the signal that triggers pain actually arises at the level of the skin. This finding provides a strong biological rationale for developing topically delivered drugs to target the pain at the source - the pain receptors in the skin. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain.ARC-4558 is a topical 0.1% clonidine gel being developed for the treatment of painful diabetic neuropathy (PDN). It is a clear, water-based, fast-drying gel that provides pain relief that rivals approved oral drugs. ARC-4558 has a minimal side-effect profile with low/undetectable systemic levels of clonidine with over 600 patients treated in clinical trials to date.

Arcion Therapeutics Headquarter Location

2400 Boston Street Suite 330

Baltimore, Maryland, 21224,

United States

410-522-8701

Latest Arcion Therapeutics News

Anesiva files for bankruptcy after Arcion merger falls through :: Scrip

Jun 16, 2017

Anesiva files for bankruptcy after Arcion merger falls through This article was originally published in Scrip 05 Jan 2010 Executive Summary Anesiva is to file for bankruptcy protection after its proposed merger with Arcion Therapeutics, which appeared to be the struggling pharmaceutical company's saviour in August, was terminated. Already Registered? Sign in to continue reading. Your login and/or password information does not match our records. Please try again. Forgot your password? Forgot your password? Enter the email address associated with your account and an email will be sent to you to reset your password. Please enter a valid email address. Unfortunately we've not been able to process this request. Submit Phone  (UK & Europe):  +44 (20) 337 73737 Phone (APAC): +61 2 8705 6907 New to Scrip? Request a free trial today! Your username does not meet the requirements. An account with that username already exists. Unfortunately we've not been able to process your registration. Please contact support. Register Your login and/or password information does not match our records. Please try again. Forgot your password? Forgot your password? Enter the email address associated with your account and an email will be sent to you to reset your password. Please enter a valid email address. Unfortunately we've not been able to process this request. Submit Phone  (UK & Europe):  +44 (20) 337 73737 Phone (APAC): +61 2 8705 6907 Authentication.SignIn.HeadSignInHeader Forgot your password? Forgot your password? Enter the email address associated with your account and an email will be sent to you to reset your password. Please enter a valid email address. Unfortunately we've not been able to process this request. Submit Phone  (UK & Europe):  +44 (20) 337 73737 Phone (APAC): +61 2 8705 6907 UsernamePublicRestriction Sorry - this email domain is not allowed. Sorry - public email accounts are not allowed. Please provide a work email address. An account with that username already exists. Unfortunately we've not been able to process your registration. Please contact support. Register All fields are required. Please make sure you have filled out all fields Please make sure you have filled out all fields Please enter a valid e-mail address Please enter a valid Phone Number Ask your question to our analysts Cancel All fields are required. For multiple recipients, separate email addresses with a semicolon. Please make sure all fields are completed. Please enter a valid e-mail address Please make sure you have filled out all fields Please make sure you have filled out all fields Subject: Anesiva files for bankruptcy after Arcion merger falls through Add a personalized message to your email Cancel Send Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe. Sign In To Set a Search Alert Your login and/or password information does not match our records. Please try again. Forgot your password?

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Arcion Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arcion Therapeutics is included in 2 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Arcion Therapeutics Patents

Arcion Therapeutics has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/21/2011

2/24/2015

Anticonvulsants, Analgesics, Amines, Antidepressants, Peripheral nervous system disorders

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/21/2011

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/24/2015

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Anticonvulsants, Analgesics, Amines, Antidepressants, Peripheral nervous system disorders

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.